(6-(Trifluoromethyl)tetrahydro-2H-pyran-3-yl)methanol | 1637310-76-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: (6-(Trifluoromethyl)tetrahydro-2H-pyran-3-yl)methanol
• 英文别名: [6-(trifluoromethyl)oxan-3-yl]methanol
• CAS: 1637310-76-9
• 化学式: C₇H₁₁F₃O₂
• 分子量: 184.158
• InChiKey: GJNCNBFWDIRUIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (6-(Trifluoromethyl)tetrahydro-2H-pyran-3-yl)methanol 在 4-二甲氨基吡啶 、 乙醇 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 生成 2-(6-(trifluoromethyl)tetrahydro-2H-pyran-3-yl)acetic acid
  参考文献：
  名称：

  [EN] MODULATORS OF ROR-GAMMA
  [FR] MODULATEURS DE ROR-GAMMA

  摘要：

  提供了式I的新化合物：其药用盐以及药物组合物，可用于治疗由RORγ介导的疾病和紊乱。还提供了包含式I新化合物的药物组合物以及它们在治疗一种或多种炎症性、代谢性、自身免疫和其他疾病或紊乱中的使用方法。

  公开号：

  WO2017024018A1
• 作为产物：
  描述：

  ethyl 6-(trifluoromethyl)tetrahydro-2H-pyran-3-carboxylate 在 lithium aluminium tetrahydride 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以160 mg的产率得到(6-(Trifluoromethyl)tetrahydro-2H-pyran-3-yl)methanol
  参考文献：
  名称：

  [EN] THIAZOLOPYRROLIDINE INHIBITORS OF ROR-GAMMA
  [FR] INHIBITEURS DU ROR-GAMMA À BASE DE THIAZOLOPYRROLIDINE

  摘要：

  公开号：

  WO2014179564A8

文献信息

• Substituted indoles as modulators of ROR-gamma
  申请人：Vitae Pharmaceuticals, LLC

  公开号：US10301261B2

  公开（公告）日：2019-05-28

  Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

  本发明提供了式 I 的新型化合物：其药学上可接受的盐及其药物组合物，它们可用于治疗由 RORy 介导的疾病和失调。还提供了包含式 I 新型化合物的药物组合物及其用于治疗一种或多种炎症、代谢、自身免疫和其他疾病或紊乱的方法。
• Substituted benzoimidazoles as modulators of ROR-γ
  申请人：Vitae Pharmaceuticals, LLC

  公开号：US10829448B2

  公开（公告）日：2020-11-10

  Provided are indole, benzoimidazole, pyrrolopyridine, and imidazopyridine derivatives and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Such derivatives include e.g., those having the Formula II: as well as pharmaceutically acceptable salts thereof. The disclosed derivatives may be used for treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

  本发明提供了吲哚、苯并咪唑、吡咯并吡啶和咪唑并吡啶衍生物及其药物组合物，可用于治疗由 RORγ 介导的疾病和失调。这类衍生物包括例如具有式 II： 及其药学上可接受的盐类。所公开的衍生物可用于治疗一种或多种炎症、代谢、自身免疫和其他疾病或紊乱。
• MODULATORS OF ROR-GAMMA
  申请人：Vitae Pharmaceuticals, LLC

  公开号：EP3331876B1

  公开（公告）日：2020-10-07
• THIAZOLOPYRROLIDINE INHIBITORS OF ROR-GAMMA
  申请人：VITAE PHARMACEUTICALS, INC.

  公开号：US20170008910A1

  公开（公告）日：2017-01-12

  Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR . Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
• [EN] THIAZALOPYRROLIDINE INHIBITORS OF ROR-GAMMA<br/>[FR] INHIBITEURS DU ROR-GAMMA À BASE DE THIAZALOPYRROLIDINE
  申请人：VITAE PHARMACEUTICALS INC

  公开号：WO2014179564A1

  公开（公告）日：2014-11-06

  Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORɣ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.